Is trade still dynamic, in sharp decline or completely insignificant? At a time when global inflation is reaching new heights and geopolitical ... balances are being reconfigured, we take a look at Sino-African relations and the issues underlying the partnerships between the continent and the Asian giant.
Any agreement must be accepted by the WTO’s 164 member countries in order to be adopted. If one country rejects the proposal, it could mean the end of the waiver.
If approved, the agreement would mean countries accounting for less than 10% of global exports of Covid-19 shots in 2021 could permit domestic manufacturers to produce vaccines without patent-holder consent for three or five years.
That would exclude China but clear India, which banned vaccine exports for much of 2021 after a wave that severely impacted the population.
The agreement would also cover Covid-19 vaccines, and after six months this would be revisited to potentially cover tests and therapeutics. This would benefit less economically developed countries that have struggled to gain access to an adequate supply of vaccinations.
Too little too late?
The agreement, first suggested by India and South Africa 18 months ago to the World Trade Organization, sought to suspend patents for successful Covid vaccines, treatments and diagnostics – invented by pharmaceutical giants such as Pfizer and Moderna – for the duration of the pandemic. Moderna pulled in more than $12bn in 2021, and Pfizer reported 92% operational growth in revenue to $81.3bn for the full year 2021.
READ MORE Who wants 300 million Covid-19 vaccines?
The continent has struggled to create its own vaccine manufacturers, but have come against obstacles, including accessing the recipe for the protected Moderna and Pfizer vaccines. The waiver would not cover technology transfer and trade secrets – something that human rights and development advocates believe will slow down developing nations’ vaccine production.
It is also important that it waves a vital article so production is not solely for domestic purposes. Removing that article means a country production vaccines can then export them to another eligible member.
Big pharma backlash
Activist groups like ONEinEU have criticised the waiver for not including all critical aspects of IP law, not just patents.
We recognize progress on the #COVID19 vaccine waiver, but:
👉A #TrueTRIPSwaiver must cover treatments & tests
👉A #TrueTRIPSwaiver must waive all critical aspects of IP, not just patents@vonderleyen & @VDombrovskis we urge you to push for a true compromise! pic.twitter.com/SLmtRFEDrW
— ONEinEU (@ONEinEU) March 16, 2022
However, the wavier has come up against resistance from drug companies, including the Global drugmakers in the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) which said the move could prohibit their ability to respond to future crises.
READ MORE BioNTech to produce vaccines in Africa
The US Chamber of Commerce released a statement on Wednesday 16 March opposing the waiver. It said: “This proposal is fundamentally misguided and should be rejected. It ignores that the overwhelming problem is not vaccine production, it is last-mile delivery, and it will erode the ability of innovative companies to develop the cure for the next pandemic or global health threat.”
It continued: “Governments and international organizations should avoid political distractions and more quickly achieve comprehensive global vaccination against Covid-19, by focusing on real, practical ongoing issues with last-mile distribution.”
Understand Africa's tomorrow... today
We believe that Africa is poorly represented, and badly under-estimated. Beyond the vast opportunity manifest in African markets, we highlight people who make a difference; leaders turning the tide, youth driving change, and an indefatigable business community. That is what we believe will change the continent, and that is what we report on. With hard-hitting investigations, innovative analysis and deep dives into countries and sectors, The Africa Report delivers the insight you need.View subscription options